Label antibodies, small molecules, proteins, or peptides with IVISense NIR fluorescent dyes.
PerkinElmer’s IVISense™ fluorescent dyes (VivoTag®) for labeling antibodies, small molecules, proteins, or peptides are designed specifically to enable customized development of novel superbright fluorescent imaging agents. Dye properties, such as excellent brightness, hydrolytic stability, and photostability, as well as selection for minimal interaction with biological tissue for no potential loss of specificity, have been optimized and validated for use in in vivo or in vitro imaging.
Available as NHS esters or maleimide reactive dyes for conjugation to either free amine (-NH3) or free thiol (-SH) containing molecules. Conjugate an optimal 1-3 dyes onto your protein or choose self-quenching dyes to make your own custom fluorogenic probes.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
IVISense 680 MAL fluorescent dye is a thiol (-SH, sulfhydryl) reactive maleimide-containing near infrared (NIR) fluorochrome for molecular labeling applications. IVISense 680 MAL fluorescent dye is optimized and integrated for both in vivo and in vitro applications. Its superior brightness makes it particularly well suited for the labeling of thiol and cysteine containing molecules for a wide range of imaging applications. Unit size 5 mg.
|IVISense NHS FLUORESCENT DYES|
|IVISense 645 NHS||643/660||Suitable for labeling free amines (typically lysine residues)|
|IVISense 680 NHS||665/688|
|IVISense 800 NHS||785/810|
|IVISense MAL FLUORESCENT DYES|
|IVISense 645 MAL||643/660||Suitable for labeling free thiols (typically cysteine residues)|
|IVISense 680 MAL||665/688|
|IVISense SELF-QUENCHING DYES|
|IVISense 680 NHS||673/691||When a protein is labeled with multiple IVISense Self-Quenching Dye molecules, there is a shift in the absorbance of the dye, which will reduce the signal. Only choose IVISense Self-Quenching Dyes if your labeling ratio of dye: protein will be 1:1. If multiple dyes are to be conjugated onto your protein, a non-self-quenching IVISense Dye should be used. NHS dyes are suitable for labeling free amines (typically lysine residues), while MAL dyes are suitable for labeling free thiols (typically cysteine residues).|
|IVISense 750 NHS||750/775|
|IVISense 750 MAL||750/775|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IVISense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Unit Size||5 mg|
|Wave Length||680 nm|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best practices, from proper probe selection to study design to imaging technique tips and tricks needed to generate meaningful biological information from your in vivo fluorescence imaging studies.
The goal of in vivo fluorescence molecular imaging is to enable non-invasive visualization and quantification of cellular and biological functioning to better understand and characterize disease processes and treatment effects earlier within the context of a biological system.
This selector guide for IVISense™ fluorescent probes is a powerful tool to help advance your oncology research. By matching probe properties to specific biology and biomarker characteristics, you can better understand how imaging and quantification of early biological changes associated with disease development, therapeutic efficacy, and drug-induced tissue changes can be realized.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.